XAIR

8-K - Beyond Air, Inc. (0001641631) (Filer)

GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7th, at The Plaza Hotel in New York. Conference  Format: One-on-one meetingsConference Dates: May 7thParticipants: Robert Goodman, CEO, and Dan Moorhead, CFO of Beyond Air    If you are interested in requesting a one-on-one meeting at the confere

8-K - Beyond Air, Inc. (0001641631) (Filer)

8-K - Beyond Air, Inc. (0001641631) (Filer)

GARDEN CITY, N.Y., April 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced it has been awarded a national group purchasing agreement for inhaled nitric oxide therapy with a leading U.S. group purchasing organization (GPO). Effective April 1, 2026, the agreement allows participating member hospitals and health systems to access the LungFit® PH system. This new agreement builds on Beyond Air's existing relationships with leading U.S. GPOs, including Vizient and Premier, Inc., further expanding access to a broad network of

GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi has resigned as Chief Executive Officer and stepped down from the Board of Directors, effective March 27, 2026, to pursue other opportunities. The Board of Directors has appointed Robert Goodman, the Company's current Chief Commercial Officer and Director, as Chief Executive Officer, effective today. For the past nine years, Mr. Lisi has led Beyond Air, guiding the development and launch of th

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals Ltd. ("XTL") relating to Beyond Air's NeuroNOS subsidiary has been terminated. The companies entered into a letter of intent in January 2026 regarding a potential transaction in which XTL would acquire Beyond Air's majority ownership interest in NeuroNOS Ltd. The letter of intent expired on March 9, 2026, in accordance with its ter

SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)

SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)

8-K - Beyond Air, Inc. (0001641631) (Filer)

10-Q - Beyond Air, Inc. (0001641631) (Filer)

424B3 - Beyond Air, Inc. (0001641631) (Filer)

EFFECT - Beyond Air, Inc. (0001641631) (Filer)

8-K - Beyond Air, Inc. (0001641631) (Filer)

S-3 - Beyond Air, Inc. (0001641631) (Filer)

8-K - Beyond Air, Inc. (0001641631) (Filer)

8-K - Beyond Air, Inc. (0001641631) (Filer)

4 - Beyond Air, Inc. (0001641631) (Issuer)

3 - Beyond Air, Inc. (0001641631) (Issuer)

8-K - Beyond Air, Inc. (0001641631) (Filer)

DEF 14A - Beyond Air, Inc. (0001641631) (Filer)

424B3 - Beyond Air, Inc. (0001641631) (Filer)

EFFECT - Beyond Air, Inc. (0001641631) (Filer)